Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis
NCT06788535
Recruiting
The purpose of this Phase 3, open label, single dose imaging study is to evaluate the efficacy and safety of I-124 evuzamitide (radioactive dye) for diagnosing Cardiac Amyloidosis in participants with suspected Cardiac Amyloidosis. The imaging test that will be used in this study is a Positron Emission Tomography Computed Tomography (PET/CT) scan.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Mayo Clinic, Scottsdale, Arizona +21 locations
Conditions: Cardiac Amyloidosis
Register for Updates
A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study
NCT06568237
Recruiting
The primary objective of the study is to evaluate the efficacy of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the study is to evaluate specific efficacy parameters of TEV-56286. Another secondary objective is to evaluate the safety and tolerability of TEV-56286. The planned study period per participant is 56 weeks including a screening period (up to 4 weeks), a 48-week double-blind treatment period, and a f... Read More
Gender:
ALL
Ages:
30 years and above
Trial Updated:
08/13/2025
Locations: Teva Investigational Site 15554, La Jolla, California +47 locations
Conditions: Multiple System Atrophy
Register for Updates
SIMPLAAFY Clinical Trial
NCT06521463
Recruiting
The primary objective is to demonstrate the safety and effectiveness of two monotherapy regimens versus dual antiplatelet (DAPT) therapy following post-implant with the WATCHMAN FLX Pro device in a commercial clinical setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: University of Alabama Birmingham, Birmingham, Alabama +77 locations
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming
NCT06536881
Recruiting
This research is being done to test the feasibility of 24-48 hours of water-only fasting to improve delivery of 4 cycles of chemotherapy in those receiving breast cancer treatment either before or after surgery.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Sibley Memorial Hospital, Washington, District of Columbia
Conditions: Breast Cancer, Early-stage Breast Cancer
Register for Updates
A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation
NCT06599502
Recruiting
This is a first-in-human, modular, Phase I/IIa, open-label, multi-centre study to assess the safety, tolerability, PK, and preliminary efficacy of AZD0022 monotherapy in combination with other anti-cancer agents in participants with tumours harbouring a KRASG12D mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Research Site, Duarte, California +43 locations
Conditions: Advanced Solid Tumours, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC)
Register for Updates
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma
NCT06742996
Recruiting
The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: University of Alabama At Birmingham Hospital, Birmingham, Alabama +147 locations
Conditions: Mantle Cell Lymphoma, B Cell Lymphoma
Register for Updates
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
NCT05897320
Recruiting
The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
08/13/2025
Locations: Ki Health Partners LLC DBA New England Institute for Clinical Research, Stamford, Connecticut +59 locations
Conditions: Episodic Migraine
Register for Updates
A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses
NCT06810934
Recruiting
The goal of this clinical trial is to test two investigational COVID-19 booster vaccines, called CoTend-s3BXBB and CoTend-BXBB, in healthy volunteers ages 40-64. The CoTend-s3BXBB vaccine includes a component called "s3", which was designed to improve the body's response to the vaccine. CoTend-BXBB is the same vaccine without s3. The main questions the study aims to answer are: 1) Is the investigational vaccine safe? 2) Does "s3" lead to bigger, broader, and longer-lasting responses to the vacc... Read More
Gender:
ALL
Ages:
Between 40 years and 64 years
Trial Updated:
08/13/2025
Locations: UCLA Westwood, Los Angeles, California +1 locations
Conditions: COVID-19
Register for Updates
Mayo Clinic Health System Northwest Wisconsin Integrated Maternal Postpartum Appointment Combination
NCT06395168
Recruiting
The purpose of this study is to explore whether combining the first post-hospital newborn provider visit and lactation consultation into a single appointment can enhance rates of successful breastfeeding initiation and continuation at predefined intervals (e.g., one week, one month, two months, three months, four months, six months, and 12 months postpartum).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Mayo Clinic Health System-Eau Claire Clinic, Eau Claire, Wisconsin
Conditions: Breast Feeding
Register for Updates
Providing an Optimized and Empowered Pregnancy for You (POPPY) Aim 3: Randomized Controlled Trial
NCT06510075
Recruiting
The PᵌOPPY study is designed to support the American Heart Association's mission to improve maternal/infant health outcomes and address inequities in maternal/infant health care. The P3OPPY Project is one of five projects within the American Heart Association P3 EQUATE Network. The overarching goal of the P3 EQUATE American Heart Association Health Equity Research Network (HERN) is to promote equity in Maternal and Infant Health outcomes by identifying innovative and cost-effective strategies to... Read More
Gender:
FEMALE
Ages:
Between 16 years and 49 years
Trial Updated:
08/13/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Pregnancy Complications, Maternal Distress, Adverse Birth Outcomes, Infant Conditions
Register for Updates
Interventions to De-implement Unnecessary Antibiotic Prescribing for Children With Ear Infections
NCT06034080
Recruiting
This study aims to improve care and reduce unnecessary antibiotic prescribing for children with ear infections. The study will compare the effectiveness of a "gold standard" to a hybrid intervention combined with this gold standard, in order to identify steps to increase parent satisfaction for child ear infection care. The "gold standard" approach is a Health System Level Intervention. On its own, it involves clinician education, tools in electronic medical records, and audit and feedback repor... Read More
Gender:
ALL
Ages:
Between 6 months and 17 years
Trial Updated:
08/13/2025
Locations: Denver Health and Hospital Authority, Denver, Colorado +2 locations
Conditions: Acute Otitis Media, Ear Infection, Pediatric Infectious Disease
Register for Updates
A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
NCT05912244
Recruiting
The researchers are doing this study to find out whether the study vaccines, IO102/IO103, given in combination with the standard-of-care drug combination, nivolumab and relatlimab, is a safe and effective treatment for people with untreated, unresectable melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Hartford Healthcare Alliance (Data Collection Only), Hartford, Connecticut +8 locations
Conditions: Melanoma
Register for Updates